The Adaptive COVID-19 Treatment Trial (ACTT)
$25,075,500N01FY2021AINIH
Leidos Biomedical Research, Inc., Frederick MD
Investigators
Abstract
To support randomized, controlled clinical trials to evaluate the safety and efficacy of investigational antiviral drugs against COVID-19.
View original record on NIH RePORTER →